



VENCLEXTA[®]
venetoclax tablets 10mg, 50mg, 100mg

VENCLEXTA + acalabrutinib

Patient Treatment Guide for Previously Untreated CLL/SLL

**An all-oral CLL treatment designed
to be completed in ~14 months**
(fourteen 28-day cycles)



Actor portrayal.

Use and Important Safety Information

Use

VENCLEXTA is a prescription medicine used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is not known if VENCLEXTA is safe and effective in children.

Important Safety Information

What is the most important information I should know about VENCLEXTA?

VENCLEXTA can cause serious side effects, including:

Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You will receive other medicines before starting and during treatment with VENCLEXTA to help reduce your risk of TLS. You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do blood tests to check for TLS when you first start and during treatment with VENCLEXTA. It is important to keep your appointments for blood tests. Tell your healthcare provider right away if you get any symptoms of TLS during treatment with VENCLEXTA, including fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, or muscle or joint pain.

**Please see additional Important Safety Information throughout the brochure.
Please see full Prescribing Information, including Medication Guide,
at www.rxabbvie.com/pdf/venclexta.pdf.**

Starting and Following Your CLL Treatment Plan

VENCLEXTA + acalabrutinib is an all-oral CLL treatment designed to be completed in ~14 months

It is important to take your treatment for the full ~14 months (56 weeks) exactly as directed

You will take VENCLEXTA + acalabrutinib according to the following treatment plan:

1

INITIATION PHASE (WEEKS 1-8): *acalabrutinib only*

- Take one **acalabrutinib** 100 mg oral tablet 2 times a day (about 12 hours apart)

2

COMBINATION TREATMENT PHASE (WEEKS 9-56): *add VENCLEXTA to acalabrutinib*

- Continue taking **acalabrutinib** 100 mg oral tablet 2 times a day (about 12 hours apart) through Week 56
- Start **VENCLEXTA** at a low dose (20 mg once daily). During “ramp-up,” you will gradually increase the dose every 7 days until you reach the full dose of 400 mg once daily (see dosing schedule on pages 4-6). Keep taking that dose through Week 56



Do not stop taking your medication or change your dose without checking with your doctor.

Once you complete ~14 months (56 weeks) of treatment, you will stop taking VENCLEXTA + acalabrutinib.

Important Safety Information (continued)

What is the most important information I should know about VENCLEXTA? (continued)

Drink plenty of water during treatment with VENCLEXTA to help reduce your risk of getting TLS. Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose, on the day of your first dose of VENCLEXTA, and each time your dose is increased.

Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you get symptoms of TLS. When restarting VENCLEXTA after stopping for 1 week or longer, your healthcare provider may check again for your risk of TLS and change your dose.

Questions You May Have About Treatment

How do I take VENCLEXTA + acalabrutinib?

- Swallow each tablet whole. Do not chew, crush, or break the tablets*
- Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA + acalabrutinib if you have side effects. If your healthcare provider changes your dosing schedule, the information in this brochure may no longer apply



Take VENCLEXTA

- Once a day with a meal and water
- About the same time each day



Take acalabrutinib

- Twice a day (about 12 hours apart)
- With a glass of water, with or without food



How much water do I need to drink each day?

- Drink 6 to 8 glasses (about 56 oz total) of water each day, paying particular attention to the 2 days before your first VENCLEXTA dose, on the day of that first dose, and each time your VENCLEXTA dose is increased
- Continue to drink at least 56 oz of water daily throughout your entire treatment. It is very important to stay hydrated while on treatment

What if I miss my dose?

- VENCLEXTA:** If it has been **less than 8 hours**, take your dose as soon as possible. If it has been **more than 8 hours**, skip the missed dose. Take the next dose at your usual time. If you vomit after taking your dose, do not take an extra dose. Take the next dose at your usual time the next day
- Acabrutinib:** Take it as soon as you remember. If it is **more than 3 hours** past your usual dosing time, skip the missed dose and take your next dose of acalabrutinib at your regularly scheduled time. Do not take an extra dose to make up for a missed dose

*Tell your healthcare provider if you have trouble swallowing 100 mg VENCLEXTA tablets. Your healthcare provider may prescribe your dose in smaller-sized tablets.

Please see additional Important Safety Information throughout the brochure. Please see full Prescribing Information, including Medication Guide, at www.rxabbvie.com/pdf/venclxxta.pdf.

Taking VENCLEXTA

For Weeks 9–12 only (during ramp-up):

4 color-coded blister packs (one per week), according to the dosing schedule inside. Tablets are marked **V** on one side with the strength (10 mg, 50 mg, or 100 mg) on the other side.



For Weeks 13–56 (after ramp-up): The VENCLEXTA medicine you will take through treatment completion comes in a pill bottle containing 100 mg pale yellow, oblong, film-coated tablets marked **V** on one side and **100** on the other side.

Important Safety Information (continued)

Who should not take VENCLEXTA?

Patients taking certain medicines during the beginning of VENCLEXTA (when the dose is being slowly increased) are at increased risk of TLS.

- Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VENCLEXTA and other medicines may affect each other causing serious side effects.
- Do not start new medicines during treatment with VENCLEXTA without first talking with your healthcare provider.

Taking acalabrutinib

For Weeks 1–56: The acalabrutinib medicine you will take for the entire treatment period comes in a pill bottle containing 100 mg orange, oval, film-coated tablets marked **ACA 100** on one side and plain on the other.



IMPORTANT! It is important to follow and complete your entire treatment plan for the full ~14 months (56 weeks).

Take your medication exactly as your healthcare provider tells you to take it.

Do not change your dose or stop taking your medication unless your healthcare provider tells you to.

Important Safety Information (continued)

Who should not take VENCLEXTA? (continued)

Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you:

- have kidney or liver problems.
- have problems with your body salts or electrolytes, such as potassium, phosphorus, or calcium.
- have a history of high uric acid levels in your blood or gout.

Please see additional Important Safety Information throughout the brochure. Please see full Prescribing Information, including Medication Guide, at www.rxabbvie.com/pdf/venclaxta.pdf.

WEEKS 1-8


Initiation Phase: acalabrutinib only

WEEKS 9-56 (through ~14 months)

Combination Treatment Phase: add VENCLEXTA to acalabrutinib

Start and continue acalabrutinib:

Take 100 mg oral tablet 2 times a day (about 12 hours apart) through Week 56



Start VENCLEXTA: Ramp-up →

Continue VENCLEXTA →

WEEK 9	WEEK 10	WEEK 11	WEEK 12	WEEK 13-56
 56 oz 10 mg × 2	 56 oz 50 mg × 1	 56 oz 100 mg × 1*	 56 oz 100 mg × 2*	 56 oz 100 mg × 4*
Take 2 VENCLEXTA 10 mg tablets DAILY for 7 days (Total: 20 mg)	Take 1 VENCLEXTA 50 mg tablet DAILY for 7 days (Total: 50 mg)	Take 1 VENCLEXTA 100 mg tablet DAILY for 7 days (Total: 100 mg)	Take 2 VENCLEXTA 100 mg tablets DAILY for 7 days (Total: 200 mg)	Take 4 VENCLEXTA 100 mg tablets DAILY for 7 days and CONTINUE through Week 56 (Total: 400 mg)

How should I store my medications?

- VENCLEXTA: Store at or below 86°F (30°C). To protect from moisture, keep tablets in their original packaging. Do not transfer the tablets to another container
- Acalabrutinib: Store acalabrutinib at room temperature between 68°F to 77°F (20°C to 25°C)

Tablets shown are not actual size.

*If you have trouble swallowing 100 mg VENCLEXTA tablets, your doctor may prescribe smaller sized tablets.

BEFORE 1ST DOSE OF VENCLEXTA

2 DAYS BEFORE



56 oz

1 DAY BEFORE



56 oz

Be sure to drink 56 oz of water for the 2 days prior to starting VENCLEXTA, on the day of your first dose of VENCLEXTA, and each time your dose is increased.

Please see additional Important Safety Information throughout the brochure. Please see full Prescribing Information, including Medication Guide, at www.rxabbvie.com/pdf/venclexta.pdf.



TREATMENT COMPLETE

START TREATMENT

Drink Water
56 oz daily

It is important to stay hydrated. Drink water every day when taking VENCLEXTA.

Pay special attention on:

- The 2 days before starting VENCLEXTA
- The 2 days at the end of each week during the VENCLEXTA Ramp-up Phase

6 to 8 glasses (about 56 oz total) each day

How should I store my medications?

- **VENCLEXTA:** Store at or below 86°F (30°C). To protect from moisture, keep tablets in their original packaging. Do not transfer the tablets to another container
- **Acalabrutinib:** Store acalabrutinib at room temperature between 68°F to 77°F (20°C to 25°C)

Important Safety Information (continued)

Who should not take VENCLEXTA? (continued)

Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you:

- are scheduled to receive a vaccine. You should not receive a “live vaccine” before, during, or after treatment with VENCLEXTA, until your healthcare provider tells you it is okay. If you are not sure about the type of immunization or vaccine, ask your healthcare provider. These vaccines may not be safe or may not work as well during treatment with VENCLEXTA.
- are pregnant or plan to become pregnant. VENCLEXTA may harm your unborn baby.

Females who are able to become pregnant:

- Your healthcare provider should do a pregnancy test before you start treatment with VENCLEXTA.
- Use effective birth control during treatment and for 30 days after the last dose of VENCLEXTA.
- If you become pregnant or think you are pregnant, tell your healthcare provider right away.

Your CLL Support Network Is Here To Help

Here are some resources to help you stay on track and manage the cost of treatment



QUESTIONS ABOUT YOUR TREATMENT?

Call our nurse* support line for VENCLEXTA

You can speak with our Registered Nurses about your treatment with VENCLEXTA—at no cost to you.

**Call our nurse support line: (844) 926-6727
Monday–Friday, 7am–7pm CST**

*The nurses from the nurse support line are provided by AbbVie and do not work under the direction of a healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.



HELP WITH PAYING FOR YOUR MEDICINE

- **VENCLEXTA Access Solutions provide in-house specialists** dedicated to helping you afford your medicine.

(888) 249-4918 / [Genentech-Access.com/VENCLEXTA](https://www.genentech.com/access/VENCLEXTA)

- **The Genentech Oncology Co-pay Assistance Program**

Genentech co-pay programs provide financial assistance to eligible commercially insured patients to help with their co-pays, co-insurance, or other out-of-pocket (OOP) costs.[†]

(855) MY-COPAY / (855) 692-6729 | [CopayAssistanceNow.com](https://www.copayassistancenow.com)

- **For financial assistance information on acalabrutinib,** visit the AstraZeneca US Patient Support website at [azpatientsupport.com](https://www.azpatientsupport.com), or call **(800) 236-9933**

[†]This Genentech Oncology® Co-pay Assistance Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)–approved indication of a Genentech medication. Patients using Medicare, Medicaid, or any other federal or state government program to pay for their medications are not eligible. Under the Program, the patient will pay a co-pay. After reaching the maximum Program benefit, the patient will be responsible for all out-of-pocket costs. All participants are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. This Program is void where prohibited by law. Genentech reserves the right to rescind, revoke, or amend the Program without notice at any time. Additional eligibility criteria apply. See full terms and conditions at [CopayAssistanceNow.com](https://www.copayassistancenow.com).

The Genentech Patient Resource Center can help answer your questions and connect you to the right Genentech patient support service. Call (877) 436-3683 to get started.

Please see additional Important Safety Information throughout the brochure. Please see full Prescribing Information, including Medication Guide, at www.rxabbvie.com/pdf/venclexta.pdf.

Important Safety Information (continued)

Who should not take VENCLEXTA? (continued)

Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you:

- are breastfeeding or plan to breastfeed. It is not known if VENCLEXTA passes into your breast milk. Do not breastfeed during treatment with VENCLEXTA and for 1 week after the last dose.

What should I avoid while taking VENCLEXTA?

You should not drink grapefruit juice or eat grapefruit, Seville oranges (often used in marmalades), or starfruit during treatment with VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood.

What are the possible side effects of VENCLEXTA?

VENCLEXTA can cause serious side effects, including:

- **Low white blood cell counts (neutropenia).** Your healthcare provider will do blood tests to check your blood counts during treatment with VENCLEXTA and may pause dosing of VENCLEXTA or give you medicines to help treat your neutropenia if it is severe.
- **Infections.** Death and serious infections such as pneumonia and blood infection (sepsis) have happened during treatment with VENCLEXTA. Your healthcare provider will closely monitor and treat you right away if you get a fever or any signs of infection during treatment with VENCLEXTA.

Tell your healthcare provider right away if you get a fever or any signs of an infection during treatment with VENCLEXTA.

The most common side effects of VENCLEXTA when used in combination with acalabrutinib in people with CLL or SLL include low white blood cell count, headache, diarrhea, muscle and bone pain, and COVID-19.

The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include low white blood cell count; low platelet count; low red blood cell count; diarrhea; nausea; upper respiratory tract infection; cough; muscle and joint pain; tiredness; and swelling of your arms, legs, hands, and feet.

Your healthcare provider may temporarily stop VENCLEXTA treatment, decrease your dose, or completely stop treatment if you get severe side effects.

VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of VENCLEXTA. Call your doctor for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you cannot afford your medication, contact genentech-access.com/patient/brands/venclaxta for assistance.

Learn More About

VENCLEXTA + acalabrutinib

for Previously Untreated CLL/SLL

An all-oral CLL treatment designed to be completed in ~14 months
(fourteen 28-day cycles)



Actor portrayal.

Scan the QR code for
full Prescribing Information,
including Medication Guide



Please see additional Important Safety Information throughout the brochure. Please see accompanying full Prescribing Information, including Medication Guide, or visit www.rxabbvie.com/pdf/venclaxta.pdf.

VENCLEXTA[®] and its design are registered trademarks of AbbVie Inc.
© 2026 AbbVie and Genentech USA, Inc. All rights reserved.
US-VENC-260066/February 2026

abbvie

Genentech
A Member of the Roche Group